Pope Janet E
Department of Medicine, Division of Rheumatology, University of Western Ontario, St. Joseph's Health Care, 268 Grosvenor Street, London, ON, N6A 4V2, Canada.
Arthritis Res Ther. 2017 Jun 6;19(1):128. doi: 10.1186/s13075-017-1347-4.
One in six patients with systemic sclerosis will develop pulmonary arterial hypertension (PAH). Screening with echocardiography and possibly pulmonary function testing (to determine the diffusing capacity of carbon monoxide) is recommended to detect PAH at a less severe stage. However, real-world screening programs have problems. Registries where echocardiograms are to be performed annually should have the best-case scenario of nearly perfect screening and referral for right heart catheterization of those highly suspect for PAH. However, registries demonstrate care gaps where patients are not referred for appropriate confirmatory testing when PAH is suspected.
六分之一的系统性硬化症患者会发展为肺动脉高压（PAH）。建议通过超声心动图以及可能的肺功能测试（以确定一氧化碳弥散能力）进行筛查，以便在病情不太严重的阶段检测出PAH。然而，现实世界中的筛查项目存在问题。每年进行超声心动图检查的登记处，对于那些高度怀疑患有PAH的患者，理应具备近乎完美的筛查和转介至右心导管检查的最佳情况。然而，登记处显示存在护理缺口，即当怀疑有PAH时，患者没有被转介进行适当的确诊检查。
